Search This Blog

Friday, September 11, 2026

Exelixis says FDA extends by 3 months review of its zanzalintinib NDA for metastatic colorectal cancer

 moving the PDUFA date to March 3, 2027

https://finviz.com/stock?t=EXEL&p=d

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)